DOCKET NO. PRD2172USPCT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lieven Meerpoel et a.

Serial No. : Not Assigned

Art Unit: Not Assigned

Filed

: Herewith

Examiner: Not Assigned

For

: N-ARYL PIPERIDINE SUBSTITUTED BIPHENYLCARBOXAMIDES

AS INHIBITORS OF APOLIPOPROTEIN B

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail in an envelope addressed to: Mail Stop PCT, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

May 24, 2006 (Date of Deposit)

David Knasiak, Reg. No. 45,991 (Name of applicant, assignee, or Registered Representative)

/David Knasiak/
(Signature)

May 24, 2006

(Date of Signature)

Commissioner for Patents Alexandria, VA. 22313

#### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

oxtimes In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
\$1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in §1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under \$1.114, no additional
fee is required.
$\square$ In accordance with \$1.129(a), this Information
Disclosure Statement is being filed in connection with $\square$ the
first or second After Final Submission, therefore:
<pre>Statement in Accordance with \$1.97(e)</pre>
(attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
☐ Statement in Accordance with \$1.97(e)

(attached); or

DOCKET NO. PRD2172USPCT

	] Please charge Deposit Account No. 10-
	0750/ ./ the fee of \$180.00 as set forth
	in §1.17(p).
П т	n accordance with \$1.97(d), this Information
<del>_</del>	Statement is being filed after the mailing date of
	nal Action under \$1.113 or a Notice of Allowance
	11 but before the payment of the Issue Fee.
	hereby petition(s) for consideration of this
	Disclosure Statement. Included are: Statement in
	with \$1.97(e) as set forth below and the fee of
\$180.00 as s	set forth in §1.17(p).
⊠ c	opies of each of the references listed on the
_	rm PTO-1449 are enclosed herewith.
accached 10	IN 110 1449 are encrosed herewren.
□ C	opies of references listed on the attached Form PTO
1449 are end	closed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
Г	] If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
	104.000.
	opies of only foreign patent documents and non-
<del>_</del>	rature are enclosed in accordance with 37 CFR 1.98
(a)(2).	acare are enerosed in accordance with 5, circ 1.50
(~/ (~/ •	

# 10/5805**30**IAP9 Rec'd PCT/PTO 24 MAY 2006

DOCKET NO. PRD2172USPCT

☐ There are no listed English language.	references which are not in the
The relevance of the not in the English language is Abstracts.	ose listed references which are s as follows: See attached
_	of a search report(s) from a lon(s), which is listed on the 609 D.
	llowing non-published pending be deemed relevant, which are sion Under MPEP 609 D.
Please charge any deficient Deposit Account No. 10-0750/PF submitted in triplicate.	ency or credit any overpayment to RD2172USPCT/DK. This form is Respectfully submitted,
	/David Knasiak/ David Knasiak Reg. No. 45,991 Attorney for Applicants
Johnson & Johnson Plaza	

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1522
DATED: May 24, 2006

## 10/580530 !AP9 Rec'd PCT/PTO 24 MAY 2006

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Date of Publication

of Cited Document

mm-dd-yyyy

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

Cite

No.1

Examiner

Initials

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 1

Kind Code<sup>2</sup>

(if known)

U.S. Patent Document

Number

a collection of information diffess it displays a valid OMB control number.			
Application Number	Not yet Assigned		
Filing Date	May 24, 2006		
First Named Inventor	Lieven Meerpoel et al		
Group Art Unit	Not yet Assigned		
Examiner Name	Not yet Assigned		
Attorney Docket Number	PRD 2172USPCT		

Pages, Columns, Lines,

where relevant passages or

relevant figures appear

**U.S. PATENT DOCUMENTS** 

Name of Patentee or Applicant

of Cited Document

					,			
				FO	REIGN PATENT DOCUMENTS			
		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Number <sup>4</sup> Kind0	Code⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T⁵
		wo	02/081460	A1	Janssen Pharmaceutica N.V	10-17-2002		
		wo	03/048121	A1	Glaxo Group Ltd.	06-12-2003		
		wo	01/96327	A1	Glaxo Group Ltd.	12-20-2001		
	<u></u>				R ART - NON PATENT LITERATURE D		in the second se	
Examiner's Initials*	anner e l'ene, l'accommendation en contract est est au l'en proprie de la contract est est est est est est est			T <sup>2</sup>				
		_	-	•				
***								
			<u> </u>				·	
Examiner Signature					Date Conside	ered	,,,,,,,	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

copy or this form with next communication to applicant.

1 Unique citation designation number: 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letterlp code (WIPO Standard ST.3). 4

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

## IAP9 Rec'd PCT/PTO 24 MAY 2006

	Application Number	Not yet Assigned
•	Filing Date	May 24, 2006
CURANCOLON UNDER MEER COOR	First Named Inventor	Lieven Meerpoel et al.
SUBMISSION UNDER MPEP 609 D	Group Art Unit	Not yet Assigned
	Examiner Name	Not yet Assigned
Page 1 of 1	Attorney Docket Number	PRD 2172USPCT

U.S. PATENT DOCUMENTS					
•			U.S. Patent Document		
Examiner Initials	Cite No. <sup>1</sup>	Name of Patentee or Applicant of Cited Document	Number	Kind Code <sup>2</sup> (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
					·
•					
		4			
	<u> </u>				
			PATENT DOCUMENTS  Foreign Patent Document		

### where relevant passages or relevant figures Name of Patentee or Cite Examiner Applicant of Cited Document appear Office<sup>3</sup> KindCode<sup>5</sup> Initials Number⁴ OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published T<sup>2</sup> Examiner Cite Initials\* PCT International Search Report dated October 27, 2005 for PCT Application. No. PCT/EP2004/053280 which relates to U.S. Patent Application filed herewith. Written Opinion of the International Searching Authority for PCT Application No. PCT/EP2004/053280

Examiner	Date	
Signature	 Considered	